secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001193125-23-274612
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Five MACs classify Sight Sciences' OMNI procedures as investigational; 63% of revenue at risk
--------------------------------------------------------------------------------

- Four new MACs (Palmetto, Celerian, NGS, Noridian) plus prior WPS LCD classify OMNI canaloplasty/trabeculotomy as investigational, effective Dec 24, 2023.
- The five MACs cover states representing ~63% of Sight Sciences' 2022 Surgical Glaucoma revenue.
- LCDs trigger 'Reimbursement Trigger Event' under MidCap credit agreement; monthly principal payments begin Jan 2024.
- If LCDs take effect, company may breach revenue covenant in 2024, allowing lender to accelerate repayment of $35M term loan.
- Company plans to engage MACs and CMS to delay or reconsider; intends to pursue reconsideration if implemented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000119312523274612/0001193125-23-274612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000119312523274612/d393470d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-274612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer